» Articles » PMID: 35857577

Hinge Disulfides in Human IgG2 CD40 Antibodies Modulate Receptor Signaling by Regulation of Conformation and Flexibility

Abstract

Antibodies protect from infection, underpin successful vaccines and elicit therapeutic responses in otherwise untreatable cancers and autoimmune conditions. The human IgG2 isotype displays a unique capacity to undergo disulfide shuffling in the hinge region, leading to modulation of its ability to drive target receptor signaling (agonism) in a variety of important immune receptors, through hitherto unexplained molecular mechanisms. To address the underlying process and reveal how hinge disulfide orientation affects agonistic activity, we generated a series of cysteine to serine exchange variants in the hinge region of the clinically relevant monoclonal antibody ChiLob7/4, directed against the key immune receptor CD40. We report how agonistic activity varies with disulfide pattern and is afforded by the presence of a disulfide crossover between F(ab) arms in the agonistic forms, independently of epitope, as observed in the determined crystallographic structures. This structural "switch" affects directly on antibody conformation and flexibility. Small-angle x-ray scattering and ensemble modeling demonstrated that the least flexible variants adopt the fewest conformations and evoke the highest levels of receptor agonism. This covalent change may be amenable for broad implementation to modulate receptor signaling in an epitope-independent manner in future therapeutics.

Citing Articles

Quantifying antibody binding: techniques and therapeutic implications.

Lodge J, Kajtar L, Duxbury R, Hall D, Burley G, Cordy J MAbs. 2025; 17(1):2459795.

PMID: 39957177 PMC: 11834528. DOI: 10.1080/19420862.2025.2459795.


An engineered palivizumab IgG2 subclass for synthetic gp130 and fas-mediated signaling.

Wittich C, Ettich J, Hertell M, Roy B, Ghosh Roy B, Xu H J Biol Chem. 2025; 301(3):108205.

PMID: 39828098 PMC: 11872477. DOI: 10.1016/j.jbc.2025.108205.


Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression.

Nguyen O, Lara S, Ferro G, Peipp M, Kleinau S Front Immunol. 2024; 15:1483617.

PMID: 39712032 PMC: 11659266. DOI: 10.3389/fimmu.2024.1483617.


Agonistic anti-NKG2D antibody structure reveals unique stoichiometry and epitope compared to natural ligands.

Fallon D, Huang C, Ma J, Morgan C, Zhou Z MAbs. 2024; 16(1):2433121.

PMID: 39582357 PMC: 11591474. DOI: 10.1080/19420862.2024.2433121.


Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8 T cells and inhibited tumor growth.

Lyu X, Zhao L, Chen S, Li Y, Yang Y, Liu H J Immunother Cancer. 2024; 12(8).

PMID: 39142717 PMC: 11331879. DOI: 10.1136/jitc-2024-008810.